Bivalent Inhibitors of c-Src Tyrosine Kinase That Bind a Regulatory Domain
Taylor K Johnson1, Matthew B Soellner1
1Departments of Medicinal Chemistry and ‡Chemistry, University of Michigan , Ann Arbor, Michigan 48109, United States.
Abstract:
We have developed a general methodology to produce bivalent kinase inhibitors for c-Src that interact with the SH2 and ATP binding pockets. Our approach led to a highly selective bivalent inhibitor of c-Src. We demonstrate impressive selectivity for c-Src over homologous kinases. Exploration of the unexpected high level of selectivity yielded insight into the inherent flexibility of homologous kinases. Finally, we demonstrate that our methodology is modular and both the ATP-competitive fragment and conjugation chemistry can be swapped.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Receptor Tyrosine Kinases
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Targeted Cancer Therapies
There are several types of targeted therapies against...


